000			a
999			_c20225 _d20225
003			OSt
005			20231202103857.0
008			231202b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_922271 _aAndika, Yustiadenta Widya
245			_aEffects of oral Mirtogenol on retinal ganglion cell apoptosis index and intraocular pressure in the Wistar glaucoma model
250			_aVol.14(3), Jul-Sep
260			_aMumbai _bWolter Kluwer _c2023
300			_a258-262p.
520			_aThe purpose of this research is to determine how Mirtogenol affects intraocular pressure (IOP) and retinal ganglion cells (RGCs) of apoptosis index in Wistar glaucoma models, as well as the relationship between IOP and RGC apoptosis index. Twelve Wistar glaucoma models were divided into two groups for experimental research with a pretest–posttest and posttest-only. The treatment group got oral administration of Mirtogenol 12.3 mg twice a day for 2 weeks, whereas the control group received a placebo in the same way. Apoptotic index and IOP were evaluated both before and after the intervention. A parametric independent t-test was used to determine the difference between groups, and a parametric paired t-test was used to determine the difference within groups. The results showed that the RGC apoptosis index in treatment groups was considerably less when compared to control groups (P < 0.001). In the treatment group, the IOP is decreased compared to the control group (mean difference: −12.67 ± 3.79 vs. 0.69 ± 4.64, respectively, P = 0.002). A significant and solid correlation was found between IOP and RGC apoptosis index (R = 0.884, P < 0.001). Thus, Mirtogenol supplementation is expected to be used to prevent glaucoma progression.
650		0	_94639 _aPHARMACEUTICS
700			_922272 _aWinarto, Silka Roudhatul Jannah
773	0		_x2231-4040 _tJournal of advanced pharmaceutical technology and research
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483914/ _yClick here
942			_2ddc _cAR